Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration

 
NEW HAVEN, CONN. & MANCHESTER, ENGLAND, June 30, 2021 - Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis”) and Oxyrane UK Ltd.(“Oxyrane”) are pleased to announce the initiation of a research collaboration.
 
Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
 
Oxyrane is developing enhanced enzyme replacement therapies (ERT) for lysosomal storage diseases (LSDs) using a proprietary, glyco-engineered yeast expression system for efficient targeting of enzymes to the lysosome. The research collaboration will focus on combining xB3TM technology and Oxyrane’s OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain.
 
Dr. Deborah Rathjen, Bioasis’ Executive Chair, said, “We are excited to be collaborating with Oxyrane on this initiative to evaluate the combination of both our technologies to meet an unmet need for patients with LSDs for enzyme replacement therapies with greater efficacy. Bioasis’ technology has demonstrated preclinical success in delivering enzyme replacement therapy into the brain and the aim of this collaboration is to fast track the development of a next generation approach to enzyme replacement therapy with the potential for improved peripheral activity combined with brain penetrance to address neurological symptoms.”
 
“We have been impressed by Bioasis’ technology for BBB delivery of enzyme replacement therapy and our technologies are very complementary so this collaboration is a natural fit. Oxyrane’s technology produces ERTs with enhanced cellular uptake and superior pharmacodynamics in a cost-efficient manner which we believe will be an overall benefit to patients,” commented Dr. Wouter Vervecken, the CEO of Oxyrane.
 
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen
 
Follow on:
Facebook
Instagram
LinkedIn
Twitter
 
 
About Bioasis
 
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit www.bioasis.us.
 
On behalf of the Board of Directors of Oxyrane UK Ltd.
 Wouter Vervecken
 
About Oxyrane
 
Oxyrane is a venture funded, pre-clinical stage biotech company dedicated to developing Enzyme Replacement Therapies (ERTs) for Lysosomal Storage Diseases. Main investors are Forbion Capital Partners (NL) and New Science Ventures (New York & London). Using its proprietary glycoengineered yeast based OxyCAT platform, the company can produce ERTs with enhanced cellular uptake and superior pharmacodynamics in a cost-efficient manner.  Oxyrane’s lead program is an Enzyme Replacement Therapy for Gaucher Disease that has demonstrated superior phamacodynamic effects in disease animal models.  https://www.oxyrane.com/